PDCD1 and non-small cell lung carcinoma: Another RCT (Checkmate 816) included resectable stage IB–IIIA NSCLC patients who underwent neoadjuvant nivolumab (PD-1 inhibitor) plus platinum-based chemotherapy (n = 179) or platinum-based chemotherapy alone (n = 179).